Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Biotinylated Feline FCGRT&B2M Heterodimer Protein, His,Avitag, produced by co-expression of FCGRT and B2M, has a calculated MW of 34.0 kDa (FCGRT) and 11.5 kDa (B2M). Subunit FCGRT is fused with a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™) and subunit Beta-2 microglobulin (B2M) contains no tag. The reducing (R) protein migrates as 36-40 kDa (FCGRT) and 18-20 kDa (B2M) respectively due to glycosylation.
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Feline FCGRT&B2M Heterodimer Protein, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
The purity of Biotinylated Feline FCGRT&B2M Heterodimer Protein, His,Avitag (Cat. No. FCN-F82W3) is more than 90% and the molecular weight of this protein is around 50-60 kDa verified by SEC-MALS.
Biotinylated Feline FCGRT&B2M Heterodimer Protein, His,Avitag (Cat. No. FCN-F82W3) captured on Biotin CAP-Series S Sensor Chip can bind Herceptin® with an affinity constant of 1.13 nM as determined in a SPR assay (Biacore T200) (QC tested).
Price(USD) : $350.00
Price(USD) : $1520.00
Price(USD) : $35.00
Price(USD) : $140.00
Price(USD) : $50.00
Price(USD) : $125.00
Price(USD) : $140.00
Price(USD) : $235.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Efgartigimod alfa | ARGX-113; EFG PH20; EFG PH20 SC; PH20 SC; ARGX-113-2308 | Approved | Argenx Se | VYVGART HYTRULO, VYVDURA, VYVGART, 卫伟迦 | United States | Myasthenia Gravis | Argenx BV | 2021-12-17 | Graves Ophthalmopathy; Tachycardia; Pemphigus; Thrombocytopenia; Guillain-Barre Syndrome; Eye Diseases; Nephrotic Syndrome; Muscular Diseases; Pemphigoid, Bullous; Optic Neuritis; Glomerulonephritis, Membranous; Rejection of organ transplantation; Purpura, Thrombocytopenic, Idiopathic; Lupus Nephritis; Scleroderma, Systemic; Sjogren's Syndrome; Stiff-Person Syndrome; Postural Orthostatic Tachycardia Syndrome; Polyneuropathies; Myositis; Nephrosis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Myasthenia Gravis | Details |
Rozanolixizumab | UCB-7665 | Approved | Ucb Sa | RYSTIGGO | United States | Myasthenia Gravis | Ucb Inc | 2023-06-27 | Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease; Encephalitis; Fibromyalgia | Details |
Efgartigimod alfa/Hyaluronidase | Approved | Argenx BV | VYVDURA, VYVGART HYTRULO | United States | Myasthenia Gravis | Argenx BV | 2023-06-20 | Polymyositis; Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Myositis; Dermatomyositis; Autoimmune Diseases; Muscular Diseases | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
IMVT-1402 | IMVT-1402; HL-161 ANS | Phase 2 Clinical | HanAll Biopharma Co Ltd | Autoimmune Diseases; Graves Disease | Details |
STSA-1301 | STSA-1301; STSA1301 | Phase 1 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Purpura, Thrombocytopenic, Idiopathic | Details |
This web search service is supported by Google Inc.